Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Juni 2021 09:05 ET | Quelle: Ultimovacs ASA

Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program

UV1/pembrolizumab results in 30% complete responses plus 30% partial responsesGood safety and tolerability profile supports expanded Phase II combination programData highlighted at ASCO in poster...
01. Juni 2021 08:00 ET | Quelle: Ultimovacs ASA

Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma

OSLO, Norway, June 01, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that a peer-reviewed...
19. Mai 2021 16:56 ET | Quelle: Ultimovacs ASA

Ultimovacs’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data

UV1/pembrolizumab results in 30% complete responses plus 30% partial responsesGood safety and tolerability profile supports use of UV1 in combination treatmentsData to be presented at ASCO and...

Vorherige Seite